Evidence map›Paper›PMID 41667820›Full record

ArticleScientific reports2026

FAM120A - a protein inserted in the ALS disease network.

Emiliano Vicencio, Laura Gomez, Sebastian Beltran, Fernanda Hernandez, Leonardo Rodriguez, Constanza Bravo, Thiare Jofré, Fabián Gálvez, Luis Labrador, Diego Rojas-Rivera and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Emiliano VicencioCenter for Integrative Biology (CIB), Faculty of Science, Universidad Mayor, Santiago, Chile.
Laura GomezCenter for Integrative Biology (CIB), Faculty of Science, Universidad Mayor, Santiago, Chile.
Sebastian BeltranCenter for Integrative Biology (CIB), Faculty of Science, Universidad Mayor, Santiago, Chile.
Fernanda HernandezCenter for Integrative Biology (CIB), Faculty of Science, Universidad Mayor, Santiago, Chile.
Leonardo RodriguezCenter for Integrative Biology (CIB), Faculty of Science, Universidad Mayor, Santiago, Chile.
Constanza BravoEscuela de Tecnología Médica, Facultad de Medicina y Ciencias de la Salud, Universidad Mayor, Santiago, Chile.
Thiare JofréEscuela de Tecnología Médica, Facultad de Medicina y Ciencias de la Salud, Universidad Mayor, Santiago, Chile.
Fabián GálvezEscuela de Tecnología Médica, Facultad de Medicina y Ciencias de la Salud, Universidad Mayor, Santiago, Chile.
Luis LabradorCenter for Integrative Biology (CIB), Faculty of Science, Universidad Mayor, Santiago, Chile.
Diego Rojas-RiveraCenter for Biomedicine (CBM), Facultad de Medicina y Ciencias de la Salud, Universidad Mayor, Santiago, Chile.
Bastián I CortésCenter for Integrative Biology (CIB), Faculty of Science, Universidad Mayor, Santiago, Chile.
Cristian CortezCenter for Genomics and Bioinformatics (CGB), Faculty of Science, Universidad Mayor, Santiago, Chile.
Patricio ManqueCenter for Integrative Biology (CIB), Faculty of Science, Universidad Mayor, Santiago, Chile.
Ute WoehlbierCenter for Integrative Biology (CIB), Faculty of Science, Universidad Mayor, Santiago, Chile. ute.woehlbier@umayor.cl.

Funding

Agencia Nacional de Investigación y Desarrollo 11240328Agencia Nacional de Investigación y Desarrollo 1150743Agencia Nacional de Investigación y Desarrollo 1230823
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a disabling and fatal neurological disease, which is characterized by the loss of motor neuron function in the brain and spinal cord. Due to genetic complexity, ALS disease is not well understood. By applying a bioinformatic approach, referred to as convergent analysis, we identified the poorly characterized protein FAM120A as a new candidate gene related to RNA metabolism, a process known to be affected during ALS disease. We studied Fam120A in the context of ALS in vivo and in vitro using an ALS mouse model and a cellular model. We found that Fam120A mRNA levels were decreased in the pre-symptomatic stage in the spinal cord of SOD1G93A mice, while Fam120A protein levels were decreased at the symptomatic stage. Fam120A was expressed mainly in neurons in the spinal cord. Overexpression of FAM120A in a motor neuron cell culture model decreased the levels of SOD1G93A aggregates. In summary, our results warrant further studies of FAM120A in the context of ALS, since it appears to be involved in disease progression and might have a role in proteostasis maintenance.

Indexed as

Amyotrophic Lateral SclerosisAnimalsDisease Models, AnimalHumansMiceMice, TransgenicMotor NeuronsSpinal CordSuperoxide Dismutase-1Superoxide Dismutase-1Amyotrophic lateral sclerosisC9orf10FAM120APURASuperoxide dismutase 1

Identifiers

PMID41667820
PMCPMC12963550

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.